Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Allergan, Inc. (AGN) Receives Good News from Japan

Page 1 of 2

Allergan plc Ordinary Shares (NYSE:AGN) received two separate pieces of good news on Tuesday. First, the Japanese Ministry of Health, Labour and Welfare granted the company a National Marketing Authorisation for the company’s BOTOX Vista, for the treatment of crow’s feet in adult patients. That’s good news owing to the fact that Japan is a wealthy country with a substantial percentage of elderly people. Medical aesthetics is a fast growing sector in the country, with a 56% increase in the occasions of non-surgical and surgical treatments performed from 2010 to 2014. The approval should help Allergan plc Ordinary Shares (NYSE:AGN) realize more profits in the country. Secondly, the FDA accepted Allergan’s NDA for oxymetazoline HCl cream 1.0% for review. The cream is for the potential treatment of a symptom associated with rosacea, which is a chronic skin condition that affects more than 16 million people in the United States. Oxymetazoline HCL cream 1.0% should have a PDUFA date in the first half of 2017.

Heading into the second quarter of 2016, a total of 170 of the hedge funds tracked by Insider Monkey were bullish on this stock, a 7% rise from one quarter earlier. According to Insider Monkey’s hedge fund database, John Paulson’s Paulson & Co has the number one position in Allergan, Inc. (NYSE:AGN), worth close to $1.45 billion, amounting to 10.7% of its total 13F portfolio. The second most bullish fund manager is Dan Loeb of Third Point, with a $1.34 billion position; 12.3% of its 13F portfolio is allocated to the stock. Remaining peers with similar optimism comprise Andreas Halvorsen’s Viking Global, Matthew Halbower’s Pentwater Capital Management, and Paul Singer’s Elliott Management.

Follow Allergan Inc (NYSE:AGN)
Trade (NYSE:AGN) Now!

The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why we will examine companies such as Sanofi SA (ADR) (NYSE:SNY), Mastercard Inc (NYSE:MA), and NIKE, Inc. (NYSE:NKE) on the next page, to gather more data points.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!